Mandate

Vinge advises Fortinova Fastigheter AB (publ) in connection with its listing on Nasdaq First North Premier Growth Market

December 15, 2020 Capital Markets and Public M&A

Vinge has advised Fortinova Fastigheter AB (publ) (“Fortinova”) in connection with its listing on Nasdaq First North Premier Growth Market (“Nasdaq First North Premier”). The prospectus was published on 6 November 2020 and the trading on Nasdaq First North Premier commenced on 19 August 2020.

The offering comprised of 18,200,000 newly issued shares and the final price in the offering was set to SEK 44 per share, corresponding to a market value of Fortinova of SEK 2,200 million after the completion of the offering.

Fortinova is a growing real estate company founded in 2010, with the business model based on acquiring, developing and managing primarily residential properties which, according to Fortinova’s assessment, have documented strong cash flows. The company has an objective to generate a positive return over time, independent of market development. Fortinova has a geographical focus on growth municipalities in western Sweden, which the company deems to have a good growth profile and are attractive areas to work and live in. As of 31 August 2020, Fortinova owned investment properties valued at SEK 2,261 million, of which residential properties make up approximately 86 per cent, with the remainder of the property value attributable to community service and commercial properties.

Vinge’s team has primarily consisted of Wibeke Sorling, Edin Agic, Jenny Sandlund, Anna Ståhlklo and Christian Riddarbo.

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026